These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31504664)

  • 1. Potential Effect of Immunotherapy Agents on Cognitive Function in Cancer Patients.
    Joly F; Castel H; Tron L; Lange M; Vardy J
    J Natl Cancer Inst; 2020 Feb; 112(2):123-127. PubMed ID: 31504664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune complications of cancer immunotherapy.
    Dhodapkar KM
    Curr Opin Immunol; 2019 Dec; 61():54-59. PubMed ID: 31557690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
    Fishman JA; Hogan JI; Maus MV
    Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapies of cancer: Is there any impact on patient cognitive functions?].
    Castel H; Joly F
    Med Sci (Paris); 2020; 36(8-9):695-699. PubMed ID: 32821042
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological complications of cancer immunotherapy.
    Roth P; Winklhofer S; Müller AMS; Dummer R; Mair MJ; Gramatzki D; Le Rhun E; Manz MG; Weller M; Preusser M
    Cancer Treat Rev; 2021 Jun; 97():102189. PubMed ID: 33872978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy.
    Liu YH; Zang XY; Wang JC; Huang SS; Xu J; Zhang P
    Biomed Pharmacother; 2019 Dec; 120():109437. PubMed ID: 31590992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Immunotherapy-Related Toxicities, Version 1.2019.
    Thompson JA; Schneider BJ; Brahmer J; Andrews S; Armand P; Bhatia S; Budde LE; Costa L; Davies M; Dunnington D; Ernstoff MS; Frigault M; Hoffner B; Hoimes CJ; Lacouture M; Locke F; Lunning M; Mohindra NA; Naidoo J; Olszanski AJ; Oluwole O; Patel SP; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wahidi M; Wang Y; Johnson-Chilla A; Scavone JL
    J Natl Compr Canc Netw; 2019 Mar; 17(3):255-289. PubMed ID: 30865922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cancer immunotherapy].
    Kjeldsen JW; Donia M; Svane IM
    Ugeskr Laeger; 2018 May; 180(21):. PubMed ID: 29804567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
    Brahmer JR; Lacchetti C; Thompson JA
    J Oncol Pract; 2018 Apr; 14(4):247-249. PubMed ID: 29517954
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy Toxicities.
    Sanchez K; Page DB; Urba W
    Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients.
    Cortellini A; Buti S; Agostinelli V; Bersanelli M
    Semin Oncol; 2019; 46(4-5):362-371. PubMed ID: 31727344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenging Cases: Management of Immune-Related Toxicity.
    Weber JS
    Am Soc Clin Oncol Educ Book; 2018 May; 38():179-183. PubMed ID: 30231403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
    Yu WD; Sun G; Li J; Xu J; Wang X
    Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
    Subudhi SK; Aparicio A; Gao J; Zurita AJ; Araujo JC; Logothetis CJ; Tahir SA; Korivi BR; Slack RS; Vence L; Emerson RO; Yusko E; Vignali M; Robins HS; Sun J; Allison JP; Sharma P
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11919-11924. PubMed ID: 27698113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications.
    Long B; Brém E; Koyfman A
    West J Emerg Med; 2020 Apr; 21(3):566-580. PubMed ID: 32421502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment after progression in the era of immunotherapy.
    Billan S; Kaidar-Person O; Gil Z
    Lancet Oncol; 2020 Oct; 21(10):e463-e476. PubMed ID: 33002442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.
    Arnaud-Coffin P; Maillet D; Gan HK; Stelmes JJ; You B; Dalle S; Péron J
    Int J Cancer; 2019 Aug; 145(3):639-648. PubMed ID: 30653255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
    Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
    Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.